GCGregory Murray Cook

Gregory Murray Cook

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gregory Murray Cook has a total of 582 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Altered physiology of drug-resistant Mycobacterium tuberculosis restricts adaptation to host-relevant conditions and produces condition-dependent collateral vulnerabilities

    by William J. Jowsey, Kate R. Harding, Caitlin E. Cunniffe, Chen-Yi Cheung, XinYue Wang, Caitlan J. Smart, Hannah R. Klaus, Amanda L. Peterson, Brunda Nijagal, Mark B. Hampton, et al.

    Antibiotic resistance mutations often disrupt essential cellular processes; however, the physiological consequences of these mutations under host-relevant conditions remain poorly understood in many bacterial pathogens. Here, we have used a combination of phenotypic growth assays and metabolomics to investigate how drug resistance affects the metabolism of Mycobacterium tuberculosis and its ability to adapt to different host-relevant conditions. This work shows that (i) the fitness costs of antibiotic resistance in M. tuberculosis are highly variable and can be exacerbated or alleviated depending on the media carbon source, (ii) genetically unrelated resistance mutations have overlapping phenotypes and metabolic dysregulation, (iii) the growth of bedaquiline- and rifampicin-resistant mutants was impaired on host-relevant carbon sources, and (iv) resistance mutants have condition-specific collateral antibiotic susceptibilities, with rifampicin-resistant mutants being hypersusceptible to ATP synthase inhibitors when grown under conditions that require propionate metabolism. Collectively, this study highlights how drug resistance impacts bacterial physiology and places metabolic constraints on the ability of M. tuberculosis to adapt to changes in host-relevant conditions. This work has major implications for our understanding of how resistance evolves within the host context and reinforces the importance of how physiological variation in M. tuberculosis might affect the outcomes of new treatment regimens. IMPORTANCE: Mutations that provide antibiotic resistance in bacterial pathogens often disrupt key cellular processes. The effects of these disruptions on cellular physiology are poorly understood, especially within the context of a host environment. In this article, we investigated how antibiotic resistance mutations affect the ability of Mycobacterium tuberculosis , the causative agent of tuberculosis, to grow under host-relevant conditions. Using techniques that characterize growth and metabolism, we demonstrate that antibiotic-resistant M. tuberculosis can have both increased and decreased growth depending on the media carbon source, highlighting how interactions between drug resistance traits and the environment affect the ability of M. tuberculosis to adapt to changing conditions. We also show that unrelated antibiotic-resistant strains share similar metabolic defects, which can be exploited to improve antimicrobial susceptibility. Overall, this work demonstrates that drug resistance reshapes the physiology of M. tuberculosis in growth-dependent ways, having major implications for our understanding of how drug resistance evolves within the host context and for the design of new treatment strategies against antibiotic-resistant M. tuberculosis .

  • Affinity-Based Proteome Profiling to Identify Targets of Tuberculosis Antibiotics

    by Liyan Huang, Kang Duan, Cara Adolph, Shengrong Li, Kiel Hards, Gregory M. Cook, Matthew B. McNeil, Zhengqiu Li

    Drug-resistant Mycobacterium tuberculosis is an increasing global health crisis that requires the urgent development of new antibiotics. Understanding the mechanism of action of new inhibitors is an essential but challenging component of drug discovery. Affinity-based proteome profiling (AfBP) is a powerful approach for target identification involving the cross-linking and selective pull-down of covalently bound target proteins. Here, we sought to investigate its utility as a technique to identify protein targets of tuberculosis drugs. We constructed photo-cross-linker probes containing a minimalist diazirine and an alkynyl handle of four TB drugs─pretomanid, linezolid, moxifloxacin, and one newly identified inhibitor, BB2-50F, with diverse chemical structures and mechanisms of action. We validated that these probes retain on-target activity against M. tuberculosis in growth and viability assays. Cross-linking and target identification using M. tuberculosis cell lysates produced results consistent with the known mechanism of each compound. The linezolid probe did not identify any proteins, consistent with linezolid binding to rRNA rather than to proteins. The pretomanid probe bound its prodrug activator Ddn, as well as Rv1558, a Ddn homologue that we show through mutagenesis and complementation studies, can bind to PMD but is unable to activate it. In addition to known targets, multiple apparent off-targets were also identified. Overall, this work highlights affinity-based proteome profiling as a useful technique to identify protein targets of tuberculosis drugs and gain insights into the drug mechanism of action.

  • Open Access

    Overcoming methicillin resistance in Staphylococcus aureus via metal ion disruption of bacterial metabolism

    by Ella K. Macbeth, Francesca Todd Rose, Chen-Yi Cheung, Nichaela Harbison-Price, David M. P. De Oliveira, Hayden G. Whyte, Mark J. Walker, Maytham Hussein, Tony Velkov, Stephanie L. Neville, et al.

    Methicillin-resistant Staphylococcus aureus (MRSA) is a significant public health threat due to both extensive antimicrobial resistance and immune evasion capabilities, necessitating alternative therapeutic strategies. Disruption of bacterial metal ion homeostasis, a process already leveraged by host nutritional immunity, represents a promising therapeutic approach. The synthetic ionophore PBT2 delivers zinc (Zn) directly into the bacterial cytosol, where it can dysregulate cellular processes and restore the efficacy of conventional antibiotics. Here, we use PBT2 and Zn (PZ) to study the cellular response to metal dysbiosis in MRSA, identifying new metal-dependent molecular vulnerabilities. Integrated transcriptomics, metabolomics and molecular analyses revealed that the antibacterial and oxacillin-resensitisation action of PZ is driven by dual metal stress: intracellular Zn accumulation and manganese (Mn) depletion. PZ disrupted central carbon metabolism at multiple key nodes, impairing glycolysis, the TCA cycle and respiration, leading to NADH and ATP depletion and compromised peptidoglycan biosynthesis. PZ also altered the metal-dependent oxidative stress response, resulting in superoxide accumulation. Collectively, this work presents the dynamic interplay between bacterial metal ion homeostasis, central metabolism, and β-lactam resistance. Uncovering how PBT2 subverts the adaptive responses of MRSA to host-imposed stresses contributes to our understanding of host-pathogen interactions and offers a foundation for developing novel antimicrobials based on metal homeostasis disruption.


  • Open Access

    Genome scale CRISPRi reveals both shared and strain-specific vulnerabilities in genetically diverse drug-resistant strains of Mycobacterium tuberculosis

    by XinYue Wang, William J. Jowsey, Chen-Yi Cheung, Nina Dickerhof, Cassandra L. Champan, Jamie R. H. Taka, Mark B. Hampton, Ghader Bashiri, Paul P. Gardner, Peter C. Fineran, et al.

    The global health burden caused by Mycobacterium tuberculosis is aggravated by the emergence and spread of drug resistance. Mutations that cause drug resistance can have collateral effects that increase the vulnerability of downstream pathways to inhibition. Here, using genome scale CRISPR interference we identified collateral effects associated with different drug-resistant genotypes of M. tuberculosis. We demonstrate that drug resistance generated shared vulnerabilities in several overlapping functional pathways. Most drug-resistant strains were more sensitive to tRNA synthetase knockdowns than the parental drug-sensitive strain, highlighting the potential of tRNA synthetases as high-value drug targets. Additionally, the rifampicin-resistant mutant RpoB(S450L) had increased sensitivity to the dysregulation of sulphur metabolism due to transcriptional dysregulation. This increased vulnerability did not translate to all rpoB genotypes but was linked to predicted effects on transcriptional dynamics. Amongst clinical isolates, non-synonymous mutations in sulphur metabolism genes have evolved in a geographic lineage specific manner to mitigate fitness costs associated with the collateral phenotypes of drug resistance. Combined, our findings highlight the power of functional genomics in pinpointing highly vulnerable drug targets across drug-resistant strains.


  • Open Access

    Aerobic soil bacteria adapt to hypoxia by hybridizing fermentation with carbon storage

    by David L. Gillett, Thilini Koralegedara, Tess F. Hutchinson, Thanh Nguyen-Dinh, Thomas D. Watts, Jessica Solari, Manasi Mudaliyar, William J. Jowsey, Nadeesha Athukorala, Wei Wen Wong, et al.

    In soil ecosystems, aerobic bacteria survive oxygen deprivation (hypoxia) by entering nonreplicative persistent states. In contrast to the well-studied metabolism of obligate and facultative anaerobes, little is known about how obligately aerobic bacteria adapt their metabolism to stay viable during hypoxia. The model obligate aerobe Mycobacterium smegmatis maintains redox homeostasis during hypoxia by mediating fermentative hydrogen production. However, the fate of organic carbon during fermentation is unresolved. Here we systematically profiled the metabolism of M. smegmatis during aerobic growth, hypoxic persistence, and the transition between these states. By integrating a differentially 13 C-labeled glucose isotopologue assay with paired metabolomics and proteomics, we observed M. smegmatis rerouted central carbon metabolism through the pentose phosphate pathway and/or Entner–Doudoroff pathways during hypoxia, while excreting high levels of hydrogen and acetate. Lipid and cryoelectron tomography analyses suggest M. smegmatis also stores carbon as glycerides in lipid droplets during hypoxia, which serve as a major reductant sink. Gene knockouts and knockdowns revealed that, while M. smegmatis depends on its hydrogen-producing hydrogenase for hypoxic survival, it can compensate for the disruption of acetate production and glyceride synthesis by producing and excreting other organic acids. We confirmed through an extensive genomic survey and biogeochemical measurements that diverse aerobic soil bacteria can store organic carbon and mediate fermentation during hypoxia. Altogether, this hybrid fermentative metabolism likely provides a competitive advantage in soils and other resource-variable environments by enabling bacteria, such as M. smegmatis , to simultaneously dispose excess reductant and maintain carbon stores during hypoxia.


  • Open Access

    Metabolic perturbation reduces antibiotic tolerance in Mycobacterium tuberculosis

    by Chen-Yi Cheung, Imogen Samuels, Hannah R. Klaus, Gregory M. Cook, Matthew B. McNeil

    Mycobacterium tuberculosis is tolerant to many antibiotics, leading to impaired antibiotic killing. Using CRISPR interference (CRISPRi) transcriptional knockdowns, we generated a panel of metabolically compromised strains to identify tolerance pathways for pursuing in therapeutic development. Disrupting the regulation of intracellular iron storage, amino acid biosynthesis and redox defence mechanisms potentiated the lethality of multiple drugs and translated to infected THP-1 macrophages. This work reinforces the role of metabolism as a major contributor to drug tolerance in M. tuberculosis.

  • Open Access

    ClpC1-targeting peptide natural products differentially dysregulate the proteome of Mycobacterium tuberculosis

    by Isabel K. Barter, Max J. Bedding, Julia Leodolter, Joshua W. C. Maxwell, Paige M. E. Hawkins, Maxwell T. Stevens, Matthew B. McNeil, William J. Jowsey, Trixie Wang, Diana Quan, et al.

    Targeting the protein quality control system in Mycobacterium tuberculosis represents a promising and underexplored opportunity for antibiotic development. The ClpC1:ClpP1P2 protease is an essential component of the system that mediates both regulatory and stress-related protein degradation. Several non-ribosomal peptide natural products, including ecumicin, ilamycins (rufomycins) and cyclomarins, have been discovered that bind to the ClpC1 chaperone of the complex and exhibit potent antimycobacterial activity, leading to significant interest in the ClpC1:ClpP1P2 system as a bona fide target for the new tuberculosis drugs. In this study, we combine quantitative proteomics, bioinformatics, transcriptomics, CRISPRi knockdown, and targeted biochemical and biophysical assays to dissect the mechanisms of ecumicin, ilamycin and cyclomarin in clinically relevant Mycobacterium tuberculosis . Strikingly, despite exhibiting similar binding modes to ClpC1, each compound induces distinct effects on protein degradation. Notably, ilamycin and ecumicin do not trigger the ClpC2 rescue mechanism that mitigates cyclomarin-induced mycobacterial toxicity. In addition, we identify a novel interaction between ecumicin and stress-response chaperone Hsp20. The differential disruption of ClpC1 substrates, stress-response chaperones, and distinct reshaping of the Mycobacterium tuberculosis proteome by the three natural products, unveils new opportunities for the development of protein quality control-targeted antimycobacterials.


  • Open Access

    Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials in Enterococcus faecalis

    by Rachel L. Darnell, Melanie K. Knottenbelt, Olivia E. Rose, Caitlin S. B. Cleary, Francesca O. Todd Rose, Hannah Hodgkinson, Yuezhou Wu, Maytham Hussein, Tony Velkov, Susanne Gebhard, et al.

    Antimicrobial tolerance, i.e., the ability to survive despite growth inhibition, is an important precursor to the development of antimicrobial resistance. However, very little is known about the evolution of drug-induced antimicrobial tolerance. Teixobactin (TXB) is an antimicrobial peptide that targets the cell envelope precursors lipid II and lipid III in Gram-positive bacteria. We have previously shown that Enterococcus faecalis displays high intrinsic tolerance to killing by TXB, and this may aid in the development of TXB resistance in this species. Here, we demonstrate that prolonged exposure to TXB led to the emergence of enhanced tolerance, but not TXB resistance. Whole-genome sequencing of these TXB-tolerant mutants identified mutations in the mevalonate and Epa (enterococcal polysaccharide antigen) biosynthesis pathways, hprK , a key regulator of carbon metabolism, and liaF , a negative regulator of the LiaSR cell envelope stress response. Increased susceptibility to TXB in single gene deletion mutants of the sensor kinase liaS and cognate response regulator liaR provides further support for a novel role of the LiaFSR cell envelope stress response system in TXB tolerance. Finally, we demonstrate that constitutive hyper-signaling of the CroRS and LiaSR cell envelope stress responses is consistent with broad tolerance to TXB and the clinically relevant antimicrobials daptomycin and ampicillin, suggesting expression profiling of the cell envelope stress response may serve as a key indicator of antimicrobial tolerance in E. faecalis .


  • Open Access

    Comparative genomics of endemic Staphylococcus aureus ST1 in New Zealand

    by Emma M. Voss, Gregory M. Cook, Christine Couldrey, Scott A. Ferguson, Chad Harland, Ali Karkaba, Scott McDougall, Sergio E. Morales, Jack Rolfe, James E. Ussher, et al.

    Staphylococcus aureus is a major zoonotic bacterial pathogen that causes a broad spectrum of human and animal diseases, including skin infections, sepsis, endocarditis, and bovine mastitis. In the geographically isolated setting of New Zealand, the population structure of S. aureus exhibits a distinct genomic profile. Globally, bovine S. aureus isolates are primarily associated with sequence types (STs), ST97 and ST151, whereas in New Zealand, ST1 predominates, accounting for approximately 70% of bovine isolates. ST1 is also a clinically significant sequence type in humans. This study employed a comparative One Health approach to investigate genetic differences in 520 S. aureus ST1 isolated from bovine milk and human clinical samples. We aimed to explore genomic features associated with persistence and diversification across hosts, focusing on antimicrobial resistance (AMR), virulence, and mobile genetic elements. Comparative genomics revealed that human isolates carried a significantly higher burden of AMR genes, consistent with clinical selective pressure. In contrast, 83% of bovine isolates harbored a prophage (φSabovST1) similar to S. aureus prophage φSaov3. This prophage encodes bovine-adapted leukocidins (LukMF’), supporting host-specific adaptation. Phylogenetic analysis revealed long branches, suggesting insufficient sampling, highlighting the need for broader genomic surveillance to resolve evolutionary relationships and transmission dynamics of S. aureus ST1 in New Zealand. These findings highlight the complex history of host interactions, historical transmission events, and ongoing bacterial adaptation. Expanding sampling efforts across human, animal, and environmental reservoirs will provide deeper insights into strain diversity, elucidate transmission pathways, and inform strategies to mitigate zoonotic risks. IMPORTANCE: This study presents a comprehensive genomic analysis of S. aureus ST1, a lineage that is unusually dominant in both bovine and human populations in New Zealand. Leveraging New Zealand’s geographical isolation, we provide critical insights into the persistence, diversification, and adaptation of S. aureus , offering valuable knowledge to advance disease prevention in both public and veterinary health and strengthening global biosecurity. The development of the first bovine ST1 reference genome serves as a valuable resource for future research, while the identification of a novel prophage (φSabovST1) carrying bovine-specific leukocidins underscores the role of mobile genetic elements in host specificity and virulence. Human isolates exhibited a higher prevalence of antimicrobial resistance genes. Phylogenetic analysis further revealed two main circulating clades of ST1 with interspersed host origins, highlighting the critical need for integrated One Health approaches to more effectively monitor and manage zoonotic pathogens across agricultural and public health systems.


  • ClpC1 Modulating Ohmyungsamycin A and Ecumicin Natural Product Analogues are Potent Antimycobacterials

    by Paige M. E. Hawkins, Max J. Bedding, David M. Hoi, Isabel K. Barter, Chen-Yi Cheung, Stefan H. Oehlers, Gregory M. Cook, Tim Clausen, Warwick J. Britton, Richard J. Payne

    Herein, we describe the design, synthesis, and evaluation of modified cyclic peptides based upon the privileged structure of the cyclic depsipeptide natural products, ohmyungsamycin and ecumicin, that target Mycobacterium tuberculosis (Mtb) caseinolytic-like protein 1 (ClpC1). Simplified analogues featuring substitution at three sites (l-Thr-3, N-Me-l-Trp-9, and/or the N-terminus) were designed and synthesized via a novel and robust strategy, employing an oxazolidine-protected C-terminal amino acid, to enable late-stage, epimerization-free, solution-phase macrolactamization. Lead analogues had nanomolar affinity for the ClpC1 N-terminal domain (NTD), possessed potent activity against Mtb in vitro and were shown to inhibit protein degradation by the mycobacterial ClpC1:ClpP1P2 protease with an associated enhancement of ClpC1 ATPase activity. The most promising analogue from the series exhibited prolonged bactericidal killing activity against Mtb without the emergence of resistance and retained activity in an in vivo zebrafish model of mycobacterial infection.